All lobbying filings

CAPITOL HILL CONSULTING GROUP

CAPITOL HILL CONSULTING GROUP filed a Q1 report for OCULAR THREPEUTIX on April 21, 2025, reporting $20,000 in lobbying income.

Lobbying for OCULAR THREPEUTIX · Biopharmaceutical company focused on therapies for the eye.

All filings by CAPITOL HILL CONSULTING GROUP · Everything OCULAR THREPEUTIX has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Income

$20,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Lobbyists on this filing 3

BRIAN SUTTER

Previously held: Staff Dir. W&M Health subcommittee, Chairman Dave Camp April'13-Dec'14. Professional Staff, W&M Health subcommittee, Chairman Dave Camp, Jan'11-April'13. Leg Dir. Rep Dave Camp, May'08-Jan'11. Leg Asst Rep Dave Camp, Feb'03-May'08. Staff Ast July'02
CHRISTOPHER DAVIS

Previously held: Staff Dir. W&M Health subcommittee, Chairman Dave Camp April'13-Dec'14. Professional Staff, W&M Health subcommittee, Chairman Dave Camp, Jan'11-April'13. Leg Dir. Rep Dave Camp, May'08-Jan'11. Leg Asst Rep Dave Camp, Feb'03-May'08. Staff Ast July'02
EMILY ELIZABETH WILKINSON-HOLLAND

Previously held: Staff -Rep. Price (2010-11), LA: Rep. Grimm (2011-12), Rep. Black (2012-13), Sen.Vitter (2013-2015), Sen. Heller (2015-17), Policy Adv. to the Sec.- Dept of HHS (3/2017-8/2017), Sr Advisor to Administrator - Ctrs for Medicare & Medicaid (8/17- 5/19).

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medicare/Medicaid

Biopharmaceutical company focused on therapies for the eye. Issues related to Medicare reimbursement for therapies of the eye.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.